Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Cancer
|
Cardiovascular
|
Infection
|
Metabolic
|
Musculoskeletal
|
CNS
|
Respiratory
|
Gastrointestinal
|
Other
|
Therapy Sector - Respiratory
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
Daiichi Sankyo sees new products, Ranbaxy taking sales to $12 billion level in three years
15 March 2010
Daiichi Sankyo is aiming to boost its group operating profit by almost 90% to ¥180 billion ($1.98 billion) in the fiscal year ending March 31st, 2013, on net sales which are seen reaching ¥1,150 billion, a 20% increase over those forecast for the ...
Pfizer faces disappointment with anticancers after more Phase III failures
12 March 2010
Pfizer is facing more disappointment with the development of some of its most advanced anticancers after Sutent (sunitinib) failed two more Phase III trials in advanced breast cancer - ending development for the drug in the disease - and figitumumab ...
US FDA advisory committees back randomised trials for LABA safety
12 March 2010
The US FDA was established in 1931, but only three years ago did it get the power to order drug makers to conduct safety studies of products that have already been approved and put into general use. Just how difficult it is going to be to use that ...
New Singapore centre to bolster Asian cancer trials
12 March 2010
Singapore has launched a new national cancer centre which it expects to play a key role in the advancement of novel therapies for malignancies prevalent in the Asia-Pacific region. The National University Cancer Institute, Singapore, was formally ...
Europe to give €12 million for influenza antiviral projects
12 March 2010
The European Commission will provide €12 million in funding for two new research projects which will develop novel influenza treatments, including against both (A) H1N1 pandemic influenza and (A) H5N1 avian flu. Speaking at an EU influenza meeting ...
 
Market Insight - Pharma sector in Turkey to shrink 25% under tough conditions
02 March 2010
The pharmaceutical industry has long eyed Turkey as one of its key emerging markets, but recent government action, which could see medicine access delayed by years, is giving it a wake-up call, ...
Market Insight - Downturn leaves HIV/AIDS funds feeling the pinch
09 February 2010
The global economic crisis has had a significant negative impact on all areas of life, including labour and property markets, national banking systems and the prices of consumer goods. With so many ...
Market Insight - How the IMI is reinvigorating European pharma research
19 January 2010
The Innovative Medicines Initiative (IMI) is a public-private partnership which aims to bolster Europe's competitive edge in pharmaceutical research and improve the mechanisms for bringing new ...
 
Xention looks to ion technology to jump start safer treatments
30 October 2009
While the patent cliff looms ever closer for big pharma, some smaller companies are not looking to untreated diseases to develop the new blockbuster but to conditions that are already catered for, ...
e-Therapeutics: leveraging unique drug discovery to secure partners
07 September 2009
As big pharma braces itself for the 2012 "winter of discontent", when several key drugs lose patent protection, these patent expiries also represent an opportunity for other firms. e-Therapeutics is ...
Archimedes – a fast mover in a niche sector
19 June 2009
Archimedes Pharma, inspired by the inventor of the screw pump, has been nurturing its own inventiveness as it sets about transforming the cancer pain market. Breakthrough cancer pain remains a ...
 
Private investment round-up: January 2010
16 February 2010
Private investments began 2010 in a much more positive fashion than at the start of 2009, but were still down on the strong finish to last year, a Scrip analysis has found. A total of 15 companies ...
Private investment round-up: December 2009
06 January 2010
The private investment market ended2009 on a high, with 14 pharmaceutical and biotech companies raising a total of $342.4 million in December, a Scrip analysis found. The amount was 8% higher than ...
Private investment round-up: November 2009
09 December 2009
Investments in private pharma and biotech companies in November fell by 16% to a still respectable $317.4 million, $13.2 million higher than in the same period last year. The main shock during the ...
 
Pharmacotherapy of pneumonia occurring in older patients
12 May 2009
The elderly population is characterized by several baseline conditions that increase the risk and modify the etiology of pneumonia. Immunosuppression caused by either concomitant morbidities or ...
Inhaled corticosteroids in COPD: systemic effects of a local therapy?
12 May 2009
Background: There are few data on the effects of inhaled corticosteroids on systemic inflammation in chronic obstructive pulmonary disease (COPD). Objective: Evaluation of the systemic ...
Toll-like receptors as therapeutic targets in cystic fibrosis
01 December 2008
Background: Toll-like receptors (TLRs) are pattern recognition receptors that act as a first-line of defence in the innate immune response by recognising and responding to conserved molecular ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm